FDA Supplement Types Explained: PAS, CBE-30, CBE-0, and Annual Report
FDA defines four reporting mechanisms for post-approval changes under 21 CFR 314.70: Prior Approval Supplement (PAS) for high-risk changes requiring FDA approval before implementation, CBE-30 for moderate-risk changes with a 30-day waiting period, CBE-0 for low-risk changes implementable immediately upon filing, and Annual Report for minimal-risk changes documented in the yearly report. Selecting the correct type requires evaluating the change's potential to adversely affect product safety, identity, strength, quality, purity, or potency.
Key Takeaways
Key Takeaways
- Four supplement types under 21 CFR 314.70 are risk-stratified: PAS (high risk, requires FDA approval), CBE-30 (moderate, 30-day wait), CBE-0 (low, immediate implementation), and Annual Report (minimal).
- When a single modification involves components requiring different reporting categories, the highest-risk component governs the filing category.
- PAS supplements have PDUFA-driven review timelines (typically 4 months for standard, 6 months for efficacy), while CBE-30 supplements have no formal review timeline.
- SUPAC guidances (IR, MR, SS) provide Level-based classification for manufacturing changes that maps directly to supplement type selection.
Overview of FDA Supplement Types
Every change to an approved NDA, ANDA, or BLA must be reported to FDA. The reporting mechanism depends on the potential risk the change poses to product quality, safety, and efficacy. This risk-based approach ensures that high-impact changes receive appropriate agency review before implementation while allowing low-impact changes to proceed without unnecessary delays.
Summary Comparison
| Feature | PAS | CBE-30 | CBE-0 | Annual Report |
|---|---|---|---|---|
| CFR Section | 314.70(b) | 314.70(c) | 314.70(d) | 314.70(e), 314.81(b)(2) |
| Risk Level | Substantial | Moderate | Minimal | Minimal |
| FDA Approval Before Implementation | Yes | No | No | No |
| Waiting Period | Until approved | 30 days | None | None |
| Distribution Before Approval | Prohibited | Prohibited during 30-day wait | Permitted | Permitted |
| PDUFA User Fee | Usually yes | Usually yes | Usually yes | No |
| Review Timeline | 4-10 months | No formal review goal (30-day wait) | No formal review goal | Reviewed as part of annual report |
| FDA Can Reverse | N/A (pre-approved) | Yes, can require PAS | Yes, can order cessation | Yes, can require supplement |
| eCTD Submission Type | Supplement (Prior Approval) | Supplement (CBE-30) | Supplement (CBE-0) | Annual Report |
Decision Framework for Selecting Supplement Type
The Central Question
The fundamental question for every post-approval change is: What is the potential for this change to adversely affect the identity, strength, quality, purity, or potency of the drug product as these factors relate to safety or effectiveness?
This is a prospective assessment. The question is not "will the change affect the product?" but "could the change affect the product?" Uncertainty about the impact pushes toward the more conservative reporting category.
Decision Tree
Using SUPAC to Determine Supplement Type
For CMC changes to oral solid dosage forms and semisolids, the SUPAC guidances provide specific mapping from change levels to supplement types:
| SUPAC Level | Supplement Type | Rationale |
|---|---|---|
| Level 1 | Annual Report | Minimal impact; well-understood changes |
| Level 2 | CBE-30 | Moderate impact; supporting data confirms no adverse effect |
| Level 3 | PAS | Substantial impact; comprehensive data and FDA review needed |
For dosage forms not covered by SUPAC (sterile injectables, inhalation products, transdermal systems, biologics), the applicant must apply the general 21 CFR 314.70 criteria.
Detailed Analysis: Prior Approval Supplement (PAS)
When Required
A PAS is required for changes that represent the highest risk category. Per 21 CFR 314.70(b)(2), these include:
Efficacy Changes:
- New indication, claim, or patient population
- Changes in dosing regimen based on new clinical data
- New dosage form (e.g., adding oral solution to existing tablet NDA)
- New route of administration
CMC Changes:
- Changes in qualitative formulation (new excipient, different excipient type)
- Quantitative formulation changes beyond SUPAC Level 2 ranges
- Changes in API synthetic route that could affect impurity profile
- Relaxation of any specification or deletion of a test
- Change in drug product sterilization method
- New manufacturing site with process or equipment changes
- Container closure changes affecting stability or extractables/leachables
Other:
- Addition of a new contract testing or manufacturing site with significant differences
- Changes that could affect bioequivalence or bioavailability
Content Requirements
A PAS must include sufficient data to allow FDA to evaluate the change without requesting additional information. The standard content includes:
| Module | Required Content |
|---|---|
| Module 1 | Cover letter, FDA Form 356h, field copy certification (if applicable), updated labeling (if applicable) |
| Module 2 | Updated Quality Overall Summary (2.3), Clinical Overview (2.5) for efficacy supplements |
| Module 3 | Updated sections relevant to the CMC change, with supporting data |
| Module 4 | Nonclinical data (if applicable to the change) |
| Module 5 | Clinical study reports (for efficacy supplements) |
Review Timeline
PAS review timelines depend on FDA's internal classification:
| Classification | Typical PDUFA Goal | Examples |
|---|---|---|
| SE (Efficacy Supplement) | 10 months (standard), 6 months (priority) | New indication |
| SEMS (Manufacturing, Sterile) | 4-6 months | Sterile manufacturing change |
| SEMN (Manufacturing, Non-Sterile) | 4-6 months | Non-sterile manufacturing change |
| SLR (Labeling Revision) | 4-6 months | Non-efficacy labeling change requiring PAS |
Detailed Analysis: CBE-30 Supplement
When Required
CBE-30 applies to changes with moderate potential impact. Per 21 CFR 314.70(c)(2), examples include:
| Category | Examples |
|---|---|
| Manufacturing site | Change to different facility with same equipment type and SOPs (SUPAC Level 2) |
| Specifications | Tightening of specification limits |
| Process | Changes in equipment within the same class; process parameter changes within validated ranges |
| Formulation | Minor excipient changes within SUPAC Level 2 ranges |
| Analytical methods | Replacement with a different analytical technology |
| Batch size | Scale changes beyond SUPAC Level 1 (>10x biobatch for IR) |
| Container closure | Changes not affecting product stability or quality |
The 30-Day Rule
The CBE-30 mechanism works as follows:
- Applicant submits the supplement to FDA
- Applicant waits 30 calendar days from FDA receipt
- During this period, the applicant may manufacture product with the change but may NOT distribute it
- If FDA does not object within 30 days, the applicant may begin distributing product with the change
- FDA retains the right to later determine the change requires a PAS
Risk Considerations
Filing a CBE-30 carries inherent business risk:
- FDA may reclassify the change as requiring PAS (during or after the 30-day period)
- Product manufactured with the change may need to be held or discarded if FDA objects
- If distributed and later rejected, recall may be necessary
Detailed Analysis: CBE-0 Supplement
When Required
CBE-0 is the most permissive reporting mechanism for supplements. It is reserved for changes with minimal potential to affect the product and specific labeling changes related to safety. Per 21 CFR 314.70(d)(2):
Labeling Changes (most common CBE-0 use):
- Adding or strengthening a contraindication, warning, precaution, or adverse reaction
- Adding or strengthening dosage and administration instructions for safer use
- Adding or strengthening statements about drug abuse, dependence, or overdose
- Deleting false, misleading, or unsupported indications for use
- Any labeling change made to comply with FDA-issued order under Section 505(o)(4)
Non-Labeling Changes:
- Editorial or minor changes to labeling
- Changes in container closure system (same material type, no impact on product)
- Changes required to comply with official compendium (USP/NF)
- Addition of an alternative analytical method of the same type (e.g., new HPLC column)
Implementation Timing
CBE-0 permits immediate implementation. The applicant may:
- Submit the supplement
- Immediately implement the change
- Immediately distribute product with the change
No waiting period is required. However, FDA retains the authority under 21 CFR 314.70(d)(3) to require the applicant to cease distribution at any time.
Safety Labeling Changes: The Most Important CBE-0 Use
The primary purpose of CBE-0 is to ensure that safety-related labeling changes reach patients and healthcare providers without delay. Under Section 505(o)(4) of the FD&C Act (FDAAA 2007), FDA has authority to require labeling changes for safety reasons. An applicant that identifies a need for a safety labeling change should not wait for FDA direction — it should file a CBE-0 proactively.
FDA's expectation is clear: when new safety information becomes available, the applicant should update the labeling via CBE-0 as soon as practicable. Waiting for FDA to mandate the change through a formal order is not acceptable if the applicant has the information first.
Detailed Analysis: Annual Report
When Appropriate
Annual reportable changes are those with the lowest potential impact. These changes are documented in the application's annual report rather than through a separate supplement submission.
Per 21 CFR 314.81(b)(2) and 314.70(e), annual reportable changes include:
| Category | Examples |
|---|---|
| Manufacturing | Changes within approved operating ranges (SUPAC Level 1) |
| Batch records | Editorial clarifications (no process change) |
| Specifications | Addition of alternative test method (same technology) |
| Stability | Routine stability testing updates |
| Imprinting | Change in tablet debossing or imprinting |
| Batch size | Changes within approved scale range |
| Equipment | Replacement with same model/type |
| Labeling | Minor editorial corrections (also reported as CBE-0 in some cases) |
Annual Report Content
The annual report is due within 60 days of the anniversary of the application's approval. It must contain:
| Section | Content |
|---|---|
| Distribution data | Quantity distributed (domestic and foreign) |
| Labeling | Current labeling, any labeling changes |
| Chemistry changes | Description of any manufacturing or controls changes filed as annual reportable |
| Nonclinical studies | Any new nonclinical data |
| Clinical studies | Published and unpublished studies involving the product |
| Adverse events | Reference to periodic safety reports |
| PMR/PMC status | Status of all post-marketing commitments and requirements |
Annual Report vs. Annual Reportable Change
These terms are related but distinct:
- Annual reportable change: A specific change to the application that is minor enough to be reported in the annual report (per SUPAC Level 1 or 21 CFR 314.70(e))
- Annual report: The comprehensive yearly filing that includes annual reportable changes along with other required information (distribution data, adverse events, etc.)
Examples by Change Category
Formulation Changes
| Change | Supplement Type | Rationale |
|---|---|---|
| Change in tablet colorant (within +/-5% by weight) | Annual Report | Non-functional excipient, minimal quantity change |
| Change in binder amount from 3% to 6% | CBE-30 | Functional excipient, within +/-10% (SUPAC Level 2) |
| Replace starch with MCC as diluent | PAS | New excipient type (qualitative change, SUPAC Level 3) |
Manufacturing Process Changes
| Change | Supplement Type | Rationale |
|---|---|---|
| Adjust blending time within approved range | Annual Report | Within approved parameters (SUPAC Level 1) |
| Replace V-blender with ribbon blender (same class) | CBE-30 | Same equipment class, different sub-class (SUPAC Level 2) |
| Change from wet granulation to direct compression | PAS | Different process type (SUPAC Level 3) |
Site Changes
| Change | Supplement Type | Rationale |
|---|---|---|
| Move compression from Building A to Building B (same campus, same equipment) | Annual Report | Within single facility (SUPAC Level 1) |
| Move to new facility with same equipment type and SOPs | CBE-30 | Different facility, same conditions (SUPAC Level 2) |
| Move to new facility with different equipment type | PAS | Different facility and equipment (SUPAC Level 3) |
Specification Changes
| Change | Supplement Type | Rationale |
|---|---|---|
| Add alternative HPLC column for assay method (same technology, validated) | Annual Report | Same technology, method validated |
| Tighten assay range from 90-110% to 95-105% | CBE-30 | Tightening improves quality |
| Widen dissolution acceptance from Q=80% to Q=70% | PAS | Relaxation increases risk |
Labeling Changes
| Change | Supplement Type | Rationale |
|---|---|---|
| Correct typographical error in prescribing information | CBE-0 | Editorial, minimal impact |
| Add newly identified adverse reaction to Warnings | CBE-0 | Safety labeling change |
| Add new indication based on clinical trial | PAS (Efficacy Supplement) | New efficacy claim |
| Remove unsupported indication | CBE-0 | Removing inaccurate information |
eCTD Formatting for Each Supplement Type
Submission Metadata
Each supplement type requires specific metadata in the eCTD regional envelope:
| Supplement Type | eCTD Submission Type | eCTD Sub-Type | Application Type |
|---|---|---|---|
| PAS | Supplement | Prior Approval | NDA, ANDA, or BLA |
| CBE-30 | Supplement | CBE-30 | NDA, ANDA, or BLA |
| CBE-0 | Supplement | CBE-0 | NDA, ANDA, or BLA |
| Annual Report | Annual Report | N/A | NDA, ANDA, or BLA |
Module 1 Requirements by Supplement Type
| Module 1 Element | PAS | CBE-30 | CBE-0 | Annual Report |
|---|---|---|---|---|
| 1.2 Cover Letter | Required | Required | Required | Required |
| 1.3.1 FDA Form 356h | Required | Required | Required | Not applicable |
| 1.3.3 Field Copy Certification | If applicable | If applicable | Not typically | Not applicable |
| 1.14 Labeling | If labeling affected | If labeling affected | If labeling change | Current labeling |
Content Depth by Supplement Type
| Data Element | PAS | CBE-30 | CBE-0 | Annual Report |
|---|---|---|---|---|
| Comparability data | Comprehensive (3+ batches) | Adequate (1-3 batches) | Minimal or none | None |
| Stability data | 3 batches accelerated + long-term | 1 batch accelerated + long-term | None typically | Routine updates |
| Dissolution data | Multi-point, multiple media | Multi-point, 1+ media | None typically | None |
| Process validation | Full validation data | Partial or commitment | None | None |
| Bioequivalence | If applicable (Level 3) | Rarely | Never | Never |
| Updated QOS (2.3) | Yes | If significant | No | No |
Common Pitfalls and How to Avoid Them
Pitfall 1: Under-Filing (Using a Less Conservative Category)
Risk: FDA rejects the supplement and requires a higher-category filing, delaying the change by months.
Prevention: When uncertain between two categories, file at the more conservative level. A CBE-30 filed as a PAS adds review time but eliminates the risk of rejection and reclassification.
Pitfall 2: Over-Filing (Using a More Conservative Category Than Needed)
Risk: Unnecessary delay and user fee expenditure.
Prevention: Carefully evaluate the change against SUPAC guidance and 21 CFR 314.70 criteria. A Level 1 change filed as a PAS wastes resources.
Pitfall 3: Combining Unrelated Changes in One Supplement
Risk: FDA may refuse the supplement or require separation, delaying all changes.
Prevention: File separate supplements for unrelated changes. Only combine changes that are part of the same overall modification.
Pitfall 4: Insufficient Supporting Data
Risk: Deficiency letter from FDA requesting additional data, delaying approval.
Prevention: Follow SUPAC data requirements precisely. Include all recommended testing data at the time of submission.
Pitfall 5: Incorrect eCTD Lifecycle Operations
Risk: Technical rejection at the gateway.
Prevention: Use replace operations for updated sections and verify leaf ID references against the cumulative dossier inventory.
Key Regulatory References
| Reference | Description |
|---|---|
| 21 CFR 314.70 | Changes to an approved NDA or ANDA |
| 21 CFR 314.71 | Procedures for submission of supplements |
| 21 CFR 314.81(b)(2) | Annual report requirements |
| 21 CFR 601.12 | Changes to an approved BLA |
| Section 506A, FD&C Act | Statutory authority for post-approval changes |
| Section 505(o)(4), FD&C Act | FDA authority for required labeling changes |
| SUPAC-IR (Nov 1995) | Change levels for immediate-release oral solids |
| SUPAC-MR (Sep 1997) | Change levels for modified-release oral solids |
| SUPAC-SS (May 1997) | Change levels for nonsterile semisolids |
| FDA Guidance: Changes to Approved NDA/ANDA (Apr 2004) | General supplement guidance |
| FDA Guidance: Comparability Protocols (Apr 2003) | Protocols for reduced reporting categories |
| ICH Q12 (Nov 2019) | Pharmaceutical product lifecycle management |
| FDA eCTD Technical Conformance Guide | eCTD formatting requirements |
References
An applicant cannot unilaterally change the supplement type after submission. If the applicant determines the change was filed under the wrong category, the appropriate action is to withdraw the supplement and resubmit under the correct type. FDA may also reclassify a supplement during review.